AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study

Stockholm, Sweden, August 17, 2023  AnaCardio, a Swedish clinical-stage biopharmaceutical company focussing on developing novel  contractile agents to treat patients with heart failure, today announced that the U.S. Food and  Drug Administration (FDA) has granted the company’s Investigational New Drug (IND)  application for the investigational drug AC01. The approval enables expansion of the clinical  development […]

AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK

Solna, Sweden and Lugano, Switzerland, April 13, 2023 AnaCardio, a Swedish clinical-stage  biopharmaceutical company focussed on developing novel contractile agents with a unique mode of-action based on the ghrelin signaling pathway, today announced that the first patient has been  successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced  ejection […]

Ghrelin treatment in heart failure patients showed increased contractility of the heart

Stockholm, Sweden, March 14 , 2023  AnaCardio´s founder Prof Lars Lund and colleagues from The Karolinska Institutet publish study on ghrelin treatment in patients with heart failure and in isolated heart cells, demonstrating increased contractility and a novel mechanism of action AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents with a […]

AnaCardio Receives Regulatory Approval to Start a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK

Stockholm, Sweden, November 17, 2022 AnaCardio today announces approval for the GOAL-HF1 Phase 1b/2a study from the competent authorities and ethics committes in Sweden, The Netherlands, Italy and the United Kingdom. This 28-day study will evaluate the effects of orally administered AC01 on safety, tolerability, pharmacokinetics and a series of pharmacodynamic readouts in patients with […]